Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of several of the Company’s products – including XIFAXAN ® 550mg/rifaximin, APRISO ® , MOVIPREP ® and SOLESTA ® - will occur during the American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting. ACG 2012 is being held in Las Vegas, NV, October 19-24, 2012.
XIFAXAN ® 550mg/Rifaximin-Related Presentations
Poster #926: Neff et al. “Outcomes in length of hospital stay in cirrhotics admitted forovert hepatic encephalopathy” Poster #927: Neff et al. “Long term survival following overt hepatic encephalopathy” Poster #1348: Neff et al. “Malnutrition in cirrhotics; daily calorie counts and nutritional deficits uncovered” Poster #P1349: Neff et al. “Readmission rates and maintenance of overt hepatic encephalopathy” Other Poster #P1571: Lembo et al. “Responsiveness of a tri-component endpoint in non- constipation irritable bowel syndrome: pooled results from two phase 3 trials, TARGET 1 and TARGET 2” Poster #P856: Kim et al. “The effect of rifaximin on staphylococcus species in the stool” Poster #P1486: Vizuete et al. “Rifaximin for the treatment of weight loss” APRISO ® -Related Presentation President’s Plenary Session Oral Presentation: Aron et al. “Mesalamine granules 1500 mg once daily for 12 weeks provides adequate relief of IBS symptoms in irritable bowel syndrome with diarrhea: results from a phase 2 trial” MOVIPREP ® -Related Presentation Plenary Session Oral Presentation: Matro et al. “The incidence of hyponatremia with two commonly prescribed purgatives for colonoscopy – polyethylene glycol 3350 with sports drink (PEG-SD) compared to polyethylene glycol with electrolyte solution (PEG-ELS)” About XIFAXAN ® (rifaximin) 550 mg tablets Important Safety Information XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age. In the trials of XIFAXAN for HE, 91 percent of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores greater than 25, and only 8.6 percent of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).